The Cognitive Deficits Screening Tools segmentation by application delineates four principal use‑cases that collectively shape market dynamics. Clinical Diagnosis—encompassing hospital neurology departments, memory clinics, and psychiatric units—accounts for the largest share, roughly 45 % of revenue, driven by mandatory screening protocols for dementia, mild cognitive impairment, and post‑stroke evaluation. Research applications, representing about 30 % of the market, include academic and pharmaceutical studies that require high‑resolution instruments for longitudinal trials and biomarker validation, thereby sustaining demand for advanced, customizable platforms. Routine Screening—performed in primary‑care offices, community health centers, and occupational health programs—contributes approximately 15 % of sales, reflecting growing public‑health initiatives aimed at early detection in aging populations. Finally, Telehealth services, now integrated with remote monitoring and virtual consultations, hold an estimated 10 % share, propelled by pandemic‑induced adoption and reimbursement reforms that expand access to digital screening solutions.